Keyword Analysis & Research: sotorasib

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
sotorasib	0.79	0.6	8601	59	9

Keyword	CPC	PCC	Volume	Score
sotorasib	1.24	0.8	5980	67
sotorasib package insert	0.53	0.7	9124	100
sotorasib fda approval	1.35	0.3	3754	25
sotorasib fda	2	0.4	6034	96
sotorasib nsclc	1.95	0.1	3248	72
sotorasib spc	0.31	0.3	7122	53
sotorasib nejm	1.82	0.8	6264	41
sotorasib odac	0.57	0.5	4958	38
sotorasib price	0.93	1	5922	95
sotorasib side effects	1.04	0.3	5606	98
sotorasib pi	1.93	0.2	880	17
sotorasib mechanism of action	1.64	0.5	5597	33
sotorasib ema	1.27	0.6	4817	92
sotorasib amgen	1.17	0.2	27	34
sotorasib kras	1.8	0.7	417	85
sotorasib label	0.03	0.3	777	33
sotorasib fachinfo	1.39	0.5	9740	100
sotorasib fda label	1.41	0.3	3383	46
sotorasib structure	1.26	0.8	7997	3
sotorasib lung cancer	1.39	0.8	7569	84
sotorasib panitumumab	1.06	0.7	7972	93
sotorasib amg510	1.51	0.4	9210	21
sotorasib chpl	1.36	0.2	5022	86
sotorasib clinical trial	1.5	0.1	9667	53
sotorasib and adagrasib	1.57	0.1	9666	97

Sotorasib - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Sotorasib

WEBSotorasib, sold under the brand names Lumakras and Lumykras, is an anti-cancer medication used to treat non-small-cell lung cancer. It targets a specific mutation, G12C, in the protein K-Ras encoded by gene KRAS which is responsible for various forms of cancer. Sotorasib is an inhibitor of the RAS GTPase family.

DA: 4 PA: 22 MOZ Rank: 21

Sotorasib is First KRAS Inhibitor Approved by FDA - NCI
cancer.gov

https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-sotorasib-lung-cancer-kras

WEBJun 25, 2021 · FDA has approved the first KRAS-blocking drug, called sotorasib (Lumakras). The approval, which covers the use of sotorasib for some patients with advanced lung cancer, was based on the results of the CodeBreak100 trial. It also sets the stage for additional KRAS inhibitors already in development, researchers said.

DA: 49 PA: 30 MOZ Rank: 20

Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2103695

WEBJun 4, 2021 · Sotorasib showed anticancer activity in patients with KRAS p.G12C–mutated advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was observed in a subgroup of...

DA: 93 PA: 10 MOZ Rank: 18

Sotorasib Uses, Side Effects & Warnings - Drugs.com
drugs.com

https://www.drugs.com/mtm/sotorasib.html

WEBSep 11, 2023 · Sotorasib is used in adults to treat non-small cell lung cancer who have already been treated with at least one other cancer medicine. Sotorasib is given when the cancer has progressed or has spread to other parts of the body or when surgery is not an option. Your doctor will make sure you have the correct tumor type to be treated with …

DA: 43 PA: 78 MOZ Rank: 88

Sotorasib - NCI - National Cancer Institute
cancer.gov

https://www.cancer.gov/about-cancer/treatment/drugs/sotorasib

WEBSotorasib is approved to treat: Non-small cell lung cancer (NSCLC) that has spread and has a KRAS p.G12C mutation. It is used in adults who have received at least one other systemic therapy. Sotorasib is approved under FDA’s Accelerated Approval Program.

DA: 64 PA: 31 MOZ Rank: 22

FDA grants accelerated approval to sotorasib for KRAS G12C …
fda.gov

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc

WEBOn May 28, 2021, the Food and Drug Administration granted accelerated approval to sotorasib (Lumakras™, Amgen, Inc.), a RAS GTPase family inhibitor, for adult patients with KRAS G12C ‑ mutated...

DA: 82 PA: 40 MOZ Rank: 45

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1917239

WEBSep 20, 2020 · Sotorasib is a small molecule that selectively and irreversibly targets KRAS G12C. Methods. We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS...

DA: 64 PA: 13 MOZ Rank: 98

FDA Approves First Targeted Therapy for Lung Cancer Mutation …
fda.gov

https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug

WEBMay 28, 2021. Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific...

DA: 89 PA: 99 MOZ Rank: 50

FDA Approves LUMAKRAS™ (Sotorasib), The First And Only ... - Amgen
amgen.com

https://www.amgen.com/newsroom/press-releases/2021/05/fda-approves-lumakras-sotorasib-the-first-and-only-targeted-treatment-for-patients-with-kras-g12cmutated-locally-advanced-or-metastatic-nonsmall-cell-lung-cancer

WEBTHOUSAND OAKS, Calif., May 28, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS ™ (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved …

DA: 63 PA: 39 MOZ Rank: 81

FDA Approval Summary: Sotorasib for KRAS G12C Mutated …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012672/

WEBApr 4, 2022 · On May 28, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib (Lumakras™, Amgen) for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with a Kirsten rat sarcoma proto-oncogene (KRAS) G12C mutation who have received at least one prior systemic therapy.

DA: 40 PA: 53 MOZ Rank: 28